Eleven new procedure and seven diagnostics codes added to private reimbursement schedule in England

The Clinical Coding and Schedule Development (CCSD) group develops and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern injection eustachian tuboplasty, extracorporeal shockwave therapy for carpal tunnel syndrome, robotic-assisted laparoscopic excision of recto-vaginal endometriosis, and diagnostic codes for alpha-melanocyte stimulating hormone, NK cell inhibition panel, XR whole spine, and others. The codes are introduced with a recommended adoption date being the 1st of February 2020. The documents also contain a list of textual changes in codes, unacceptable combinations, and inactivated codes.

The CCSD Group has approved the following procedure codes for publication to the CCSD Schedule in October 2019 with a recommended adoption date being the 1st of February 2020:

• Injection eustachian tuboplasty (D2241)
• Robotic-assisted revision of total replacement of knee joint (W4231)
• Extracorporeal shockwave therapy for carpal tunnel syndrome (T6570)
• Infracoccygeal sacropexy without mesh to repair vaginal vault prolapse +/- ureterolysis (P2454)
• Ultraviolet irradiation of riboflavin for epithelium off cross-linking of corneal collagen (C5131)
• Ultraviolet irradiation of riboflavin for epithelium on cross-linking of corneal collagen (C5132)
• Endovascular insertion of an intravascular wire-mesh blood-flow disruption device for intracranial aneurysms (L3330)
• Cytoreductive surgery for stage III epithelial ovarian malignancies including Heated Intraperitoneal Chemotherapy (HIPEC) (J9908)
• Robotic-assisted laparoscopic excision of recto-vaginal endometriosis including rectal shave, +/-ureterolysis (P3195)
• Robotic-assisted laparoscopic excision of recto-vaginal endometriosis including disc resection of rectum, +/-ureterolysis (P3196)
• Robotic-assisted laparoscopic excision of recto-vaginal endometriosis including bowel resection (including formation of stoma) +/- hysterectomy, +/-ureterolysis (P3197)

See full details here.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in October 2019 with a recommended adoption date being the 1st of February 2020:

• FoundationOne Heme (7007G)
• Hailo Dx Immunoscore Colon (0002T)
• Alpha-Melanocyte Stimulating Hormone (0006B)
• NK Cell Inhibition Panel (0007B)
• NK Assay Full Panel (0008B)
• XR whole spine (IM373)
• Circulating tumor DNA profile for lung cancer (Guardant 360) (3104G)

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.